gemcitabine has been researched along with mitoxantrone in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (62.50) | 29.6817 |
| 2010's | 11 (34.38) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Abu-Rustum, N; Barakat, RR; Brown, CL; Chi, DS; Curtin, JP; Hoskins, WJ; Husain, A; Poynor, EA; Prasad, M | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hurwitz, H; Jacobson, R; Laughlin, MJ; Moore, JO; Petros, WP; Rizzieri, DA; Rosner, GL | 1 |
| Boehrer, S; Bojunga, J; Chow, KU; Fauth, F; Hoelzer, D; Martin, H; Mitrou, PS; Rummel, MJ; Schneider, B; Stieler, M; Weidmann, E | 1 |
| Apostolidou, E; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A | 1 |
| Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N | 1 |
| Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD | 1 |
| Ahmad, I; Dritschilo, A; Gokhale, PC; Kasid, UN; Pei, J; Rahman, A; Zhang, C | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Akrivakis, K; Flath, B; Heilmann, V; Kreienberg, R; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O | 1 |
| Benedetti, G; De Pangher Manzini, V; Del Conte, G; dell'Amore, D; Galetta, D; Giaquinta, S; Lopez, M; Marino, A; Martoni, A; Mazzanti, P; Piana, E; Pinto, C | 1 |
| Aravantinos, G; Bacoyiannis, H; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Koutras, A; Makatsoris, T; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E | 1 |
| Cordes, T; Fischer, D; Friedrich, M; Lüdders, D; Maass, N; Schroer, A; Villena-Heinsen, C | 1 |
| Marik, PE; Vahid, B | 1 |
| Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR | 1 |
| Flynn, PJ; Garbo, LE; Kolibaba, KS; MacRae, MA; Rauch, MA; Wang, Y | 1 |
| Halldén, G | 1 |
| Advani, AS; Ali-Osman, F; Barker, A; Beaven, A; Copelan, E; de Castro, CM; Diehl, LF; Kalaycio, M; Moore, JO; Rizzieri, DA; Rybicki, L; Sekeres, MA; Shadman, M; Sobecks, R; Talea, P | 1 |
| Ai, Y; Brody, JR; Burkhart, RA; Cozzitorto, JA; Gehrmann, M; Lal, S; Liang, Q; Miller, K; Napper, A; Norris, ZA; Peng, Y; Sawicki, JA; Talbott, VA; Tholey, RM; Winter, JM; Witkiewicz, AK; Yeo, CJ; Zhuang, Z | 1 |
| Atxner, J; Buchwald, D; Happe, A; Kröz, M; Matthes, H; Popp, S; Schad, F | 1 |
| Baumgartner, S; Kunz, M; Urech, K; Weissenstein, U | 1 |
| Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y | 1 |
| Gu, M; Li, F; Liu, J; Sun, Y; Wei, Y; Xiong, Y; Zhu, L | 1 |
| Guo, Y; Hu, Y; Huang, Y; Liu, D; Lu, B; Wang, X; Zhu, Z | 1 |
4 review(s) available for gemcitabine and mitoxantrone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Adjuvant and additive therapy for cancer of the pancreas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Folic Acid; Gemcitabine; Hematinics; Humans; Leucovorin; Male; Mitoxantrone; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Surveys and Questionnaires; Time Factors | 2003 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
10 trial(s) available for gemcitabine and mitoxantrone
| Article | Year |
|---|---|
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mitoxantrone; Neural Tube Defects | 2002 |
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Mouth Mucosa; Pilot Projects; Remission Induction; Salvage Therapy; Sepsis; Stomatitis; Treatment Outcome | 2003 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Heart Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Salvage Therapy; Soft Tissue Neoplasms | 2003 |
Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neutropenia | 2005 |
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Italy; Male; Mesothelioma; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Staging; Pleural Neoplasms; Retrospective Studies; Treatment Outcome | 2006 |
Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate | 2006 |
Feasibility and efficacy of chemotherapy with gemcitabine mono and with paclitaxel/mitoxantron in gynaecological cancers.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Palliative Care; Survival Analysis | 2007 |
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Half-Life; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Salvage Therapy; Tissue Distribution; Vidarabine | 2008 |
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; Drug Resistance, Multiple; Equilibrative-Nucleoside Transporter 2; Female; Fever; Gemcitabine; Gene Expression Regulation, Leukemic; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Infusions, Intravenous; K562 Cells; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Multidrug Resistance-Associated Proteins; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; U937 Cells | 2010 |
18 other study(ies) available for gemcitabine and mitoxantrone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The role of laparoscopy in second-look evaluations for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Injections, Intravenous; Laparoscopy; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Reoperation; Retrospective Studies | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Cladribine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Mitoxantrone | 2002 |
Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Liposomes; Male; Mice; Mice, Nude; Mitoxantrone; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-raf; Taxoids; Xenograft Model Antitumor Assays | 2004 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Gemcitabine; Gene Silencing; High-Throughput Screening Assays; Humans; Mitoxantrone; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Thiolester Hydrolases | 2013 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Retrospective Studies; Survival Rate; Ultrasonography, Interventional; Viscum album | 2014 |
Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Herb-Drug Interactions; Humans; Male; Mitoxantrone; Neoplasms; Plant Extracts; Plants, Medicinal; Taxoids; Viscum album | 2014 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, Lewis Lung; CD3 Complex; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Lymphocyte Count; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mitomycin; Mitoxantrone; Neoplasm Transplantation; Neoplasms, Experimental; Protein Transport; T-Lymphocytes; Tumor Microenvironment | 2015 |
Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzothiazoles; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Intracellular Space; Luciferases, Firefly; Luminescence; Luminescent Measurements; Mitoxantrone; Neoplasm Proteins; Pancreatic Neoplasms; Up-Regulation | 2016 |
Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2.
Topics: Adaptor Proteins, Signal Transducing; Annexin A2; Anti-Bacterial Agents; Antineoplastic Agents; Azithromycin; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoroquinolones; Gemcitabine; Humans; Liver Neoplasms; Mitoxantrone; Moxifloxacin; Mycoplasma hyorhinis; Protein Binding; Real-Time Polymerase Chain Reaction | 2017 |